2 results match your criteria: "Theageneion Cancer Center[Affiliation]"
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Blood
September 2015
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
Ann Hematol
May 2007
Department of Hematology, Theageneion Cancer Center, Thessaloniki, Greece.
The aim of the study was to evaluate the role of hypochromic erythrocytes (HYPO%) compared to "traditional" and novel markers of iron status and erythropoiesis in recognizing iron-restricted erythropoiesis (IRE) and predicting response to erythropoietin (rHuEPO) in anemic patients with myeloma and lymphoma. Forty-one newly diagnosed patients who received epoetin-beta at a subcutaneous weekly dose of 30,000 IU for 6 weeks were studied. Response to rHuEPO was observed in 27 patients (65.
View Article and Find Full Text PDF